Lilly Lifts FY17 View As Q3 Results Top Estimates; Mulls IPO Or Sale Of Elanco

Drug maker Eli Lilly And Co. on Tuesday said it has raised its fiscal 2017 forecast for adjusted earnings per share and revenues, both above market estimates. In its third quarter, net income declined, while adjusted earnings and top line beat market view.Further, the company said it is reviewing strategic alternatives for Elanco Animal Health, including an initial public offering, merger, sale...

from RTT - Earnings http://ift.tt/2gxjBX8
via IFTTT